95%Confidence
0Views
FDASource
2026-03-07Date
Summary
Third testosterone product recall for Asteria Health indicates widespread contamination problems across their product line. This suggests fundamental quality control failures that could jeopardize the company's entire operations and license.
Actionable: Completely avoid investments in Asteria Health and alert healthcare providers to alternative testosterone sources.
AI Confidence: 95%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 25.0 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now